What question did this study set out to answer?

To examine the relationship between systemic venetoclax concentrations, concurrent use of CYP3A inhibitors, and the incidence of haematological adverse events in patients with acute myeloid leukaemia.

January 7, 2026Frontiers in PharmacologyOpen Access

Venetoclax concentration affects the incidence of haematological adverse events in patients with acute myeloid leukaemia

View Full Paper

Ask AI

Bookmark

Authors

JCJing Chen XYX. Jessie Yang JXJingxian Xie

Discussion

Member takes

Overview

Retrospective study shows higher venetoclax exposure increases severe haematological toxicities in acute myeloid leukaemia, indicating drug monitoring may prevent adverse events.

Key Points

To examine the relationship between systemic venetoclax concentrations, concurrent use of CYP3A inhibitors, and the incidence of haematological adverse events in patients with acute myeloid leukaemia.
Retrospectively analyzed data from 114 patients receiving venetoclax therapy across four drug combinations: venetoclax plus azacitidine alone (n=52) or with omeprazole (n=20), voriconazole (n=20), or posaconazole (n=22).
Determined plasma steady-state minimum (Cmin) and peak (Cmax) concentrations of venetoclax, as well as steady-state Cmin for voriconazole and posaconazole, using high-performance liquid chromatography.
Venetoclax systemic concentrations were highest when combined with posaconazole or voriconazole, followed by omeprazole, and were lowest with venetoclax plus azacitidine alone.
Elevated venetoclax exposure significantly increased the incidence of Grade 3 or higher haematological adverse events, driven by concurrent CYP3A inhibitor administration.
A venetoclax Cmax threshold of 4,886.00 ng/mL demonstrated the strongest predictive utility for identifying patients at risk of Grade ≥3 neutropenia and thrombocytopenia.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a85abedf8226fba7f10a6ee https://doi.org/10.3389/fphar.2025.1710282

View Full Paper

Ask AI

Bookmark

January 7, 2026Frontiers in PharmacologyOpen Access

Venetoclax concentration affects the incidence of haematological adverse events in patients with acute myeloid leukaemia

View Full Paper

Ask AI

Bookmark

Authors

JCJing Chen XYX. Jessie Yang JXJingxian Xie

Discussion

Member takes

Overview

Retrospective study shows higher venetoclax exposure increases severe haematological toxicities in acute myeloid leukaemia, indicating drug monitoring may prevent adverse events.

Key Points

To examine the relationship between systemic venetoclax concentrations, concurrent use of CYP3A inhibitors, and the incidence of haematological adverse events in patients with acute myeloid leukaemia.
Retrospectively analyzed data from 114 patients receiving venetoclax therapy across four drug combinations: venetoclax plus azacitidine alone (n=52) or with omeprazole (n=20), voriconazole (n=20), or posaconazole (n=22).
Determined plasma steady-state minimum (Cmin) and peak (Cmax) concentrations of venetoclax, as well as steady-state Cmin for voriconazole and posaconazole, using high-performance liquid chromatography.
Venetoclax systemic concentrations were highest when combined with posaconazole or voriconazole, followed by omeprazole, and were lowest with venetoclax plus azacitidine alone.
Elevated venetoclax exposure significantly increased the incidence of Grade 3 or higher haematological adverse events, driven by concurrent CYP3A inhibitor administration.
A venetoclax Cmax threshold of 4,886.00 ng/mL demonstrated the strongest predictive utility for identifying patients at risk of Grade ≥3 neutropenia and thrombocytopenia.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a85abedf8226fba7f10a6ee https://doi.org/10.3389/fphar.2025.1710282

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark